Lilly raises UK Mounjaro list prices by up to 170%

Eli Lilly increased its UK list prices for the Mounjaro (tirzepatide) KwikPen effective September 1, 2025, and the UK's Department of Health and Social Care redetermined NHS reimbursement prices to match, so pharmacies would not lose money filling prescriptions ^[1][2].

The increases are steep and get larger at higher doses. The 2.5 mg pen went from £92 to £133. The 5 mg pen also went from £92, but to £180. The 7.5 mg and 10 mg pens each went from £107 to £255. The 12.5 mg and 15 mg pens each went from £122 to £330 ^[1][2]. That works out to roughly a 45% increase at the starting dose and about 170% at the top doses.

Community Pharmacy England said Lilly made the change "to address pricing inconsistencies compared to other developed countries, including in Europe," and that Lilly "has reached an agreement with the NHS to ensure continued supply and patient access" ^[2]. The sources do not disclose the terms of that agreement, and they do not say what Lilly's net prices are after any confidential discounts — list prices and what a health system actually pays are often different.

There is a timing wrinkle for UK pharmacies. The redetermined reimbursement prices apply to September prescriptions even though the September 2025 Drug Tariff still showed the old list prices; the new prices were set to appear in the October 2025 Drug Tariff ^[2]. NHS Business Services Authority confirmed the change applies to branded prescriptions dispensed from September 2025 as well ^[1].

The private market is a separate question

Most UK patients who get tirzepatide for weight loss pay for it privately, and the sources are explicit that this piece is unsettled. Lilly "does not determine the prices that private healthcare providers set," but says it is working with them to maintain access ^[2]. Lilly offered a commercial agreement to all private providers to support dispensing of private prescriptions; pharmacies that do not dispense private Mounjaro prescriptions were advised not to accept it, and those that decline can still get stock for NHS dispensing as usual ^[2].

Community Pharmacy England acknowledged "growing concerns regarding Mounjaro® pricing and supply arrangements for private services offered by many pharmacies," but said its remit covers only NHS pharmacy services, so it could not address private supply questions ^[2]. In other words, how much UK patients paying out of pocket end up spending is not settled by these documents.

Why it matters for patients

If you are in the US, none of these prices apply to you directly. US list prices, insurance coverage and self-pay programs for Mounjaro and Zepbound are set separately, and these sources say nothing about US pricing. Any change to what Americans pay is not addressed here.

What is relevant is the stated reason. Lilly is raising prices in one wealthy country explicitly because its prices there looked inconsistent with prices in other developed countries ^[2]. That is the logic of international price comparison working in the upward direction: rather than only lowering prices in high-cost markets, a manufacturer can raise them in lower-cost ones. For US patients following debates about why American drug prices are higher than those abroad, this is a concrete example of how a company can respond to that gap.

It also shows how quickly a national health system can absorb a list-price jump. The DHSC matched reimbursement to the new list prices within the same month so dispensing would not happen at a loss ^[1][2]. The cost effect lands on the payer, not the pharmacy — at least on the NHS side.

Finally, the dose-tiered structure is worth noting. The old UK prices were nearly flat across strengths: £92 to £122 from lowest to highest ^[1]. The new ones are not, ranging from £133 to £330 ^[1]. Flat pricing across doses has been a feature of some GLP-1 pricing in the US too, and this change shows that structure is not fixed.

What happens next

The new reimbursement prices took effect for prescriptions dispensed from September 2025 and were scheduled to appear in the October 2025 Drug Tariff ^[2]. What private UK providers charge, and whether Lilly makes similar list-price moves in other countries, is not stated in these sources.